Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Lu, Nan ^a,b   Sun, Hanxiao ^a,b   Yu, Jingjia ^a   Wang, Xiaojing ^a   Liu, Dongmei ^a   Zhao, Lin ^a   Sun, Lihao ^a   Zhao, Hongyan ^a   Tao, Bei ^a   Liu, Jianmin ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; FAT DROPLET; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIRAGLUTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR RUNX2; ANABOLIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW STROMA CELL; BONE MASS; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFORMATION; MORNING DOSAGE; NONHUMAN; OSTEOBLAST; OVARIECTOMY; PHENOTYPE; RAT; REAL TIME POLYMERASE CHAIN REACTION; AGONISTS; ANIMAL; BONE; BONE DENSITY; BONE DEVELOPMENT; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; MALE; MESENCHYMAL STROMA CELL; METABOLISM; OSTEOPOROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADIPOGENESIS; ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY; CELLS, CULTURED; DIABETES MELLITUS; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; LIRAGLUTIDE; MALE; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; PPAR GAMMA; RATS; RATS, WISTAR;

EID: 84941312682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132744     Document Type: Article

References (42)

1. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. The American journal of medicine. 2011;124 (1 Suppl):S3-18. doi: 10.1016/j.amjmed.2010.11. 002 PMID: 21194578.
2. Kazafeos K. Incretin effect: GLP-1, GIP, DPP4. Diabetes Res Clin Pract. 2011;93 Suppl 1:S32-6. Epub 2011/09/01. doi: S0168-8227 (11) 70011-0 [pii]doi: 10.1016/S0168-8227 (11) 70011-0 PMID: 21864749.
3. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50(11):2530-9. PMID: 11679431.
4. Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert opinion on investigational drugs. 2012;21(1):45-57. doi: 10.1517/13543784.2012.638282 PMID: 22111970.
5. Drucker DJ. The biology of incretin hormones. Cell metabolism. 2006;3(3):153-65. doi: 10.1016/j. cmet.2006.01.004 PMID: 16517403.
6. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-16. doi: 10.1016/S0140-6736 (09) 61375-1 PMID: 19853906.
7. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell metabolism. 2013;17(6):819-37. doi: 10.1016/j.cmet.2013.04.008 PMID: 23684623.
8. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine reviews. 2012;33(2):187-215. doi: 10.1210/er.2011-1052 PMID: 22323472; PubMed Central PMCID: PMC3528785.
9. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS drugs. 2012;26(10):871-82. doi: 10.2165/11635890-000000000-00000 PMID: 22938097.
10. Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, et al. Exendin-4, aGLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63(11):3891-905. doi: 10.2337/db13-1169 PMID: 24879833.
11. Nuche-Berenguer B, Portal-Nunez S, Moreno P, Gonzalez N, Acitores A, Lopez-Herradon A, et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. Journal of cellular physiology. 2010;225(2):585-92. Epub 2010/05/28. doi: 10.1002/jcp. 22243 PMID: 20506394.
12. Nuche-Berenguer B, Moreno P, Esbrit P, Dapia S, Caeiro JR, Cancelas J, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcified tissue international. 2009;84(6):453-61. Epub 2009/02/17. doi: 10.1007/s00223-009-9220-3 PMID: 19219381.
13. Nuche-Berenguer B, Moreno P, Portal-Nunez S, Dapia S, Esbrit P, Villanueva-Penacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2010;159(1-3):61-6. Epub 2009/07/10. doi: S0167-0115 (09) 00148-7 [pii] doi: 10.1016/j.regpep. 2009.06.010 PMID: 19586609.
14. Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, Moreno P, Marinoso ML, Esbrit P, et al. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. The Journal of endocrinology. 2011;209(2):203-10. Epub 2011/03/05. doi: JOE-11-0015 [pii] doi: 10.1530/JOE-11-0015 PMID: 21372151.
15. Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2013;28(7):1641-52. Epub 2013/02/22. doi: 10.1002/jbmr.1898 PMID: 23427056.
16. Sanz C, Vazquez P, Blazquez C, Barrio PA, Alvarez Mdel M, Blazquez E. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. American journal of physiology Endocrinology and metabolism. 2010;298(3):E634-43. Epub 2009/12/31. doi: ajpendo.00460.2009 [pii] doi: 10.1152/ajpendo.00460.2009 PMID: 20040695.
17. Abdallah BM, Kassem M. New factors controlling the balance between osteoblastogenesis and adipogenesis. Bone. 2012;50(2):540-5. doi: 10.1016/j.bone.2011.06.030 PMID: 21745614.
18. Taipaleenmaki H, Abdallah BM, Al Dahmash A, Saamanen AM, Kassem M. Wnt signalling mediates the cross-talk between bone marrow derived pre-adipocytic and pre-osteoblastic cell populations. Experimental cell research. 2011;317(6):745-56. doi: 10.1016/j.yexcr.2010.12.015 PMID: 21211534.
19. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2010;25(7):1468-86. doi: 10.1002/jbmr.141 PMID: 20533309.
20. Ko CH, Siu WS, Wong HL, Shum WT, Fung KP, San Lau CB, et al. Pro-bone and antifat effects of green tea and its polyphenol, epigallocatechin, in rat mesenchymal stem cells in vitro. Journal of agricultural and food chemistry. 2011;59(18):9870-6. doi: 10.1021/jf202015t PMID: 21877759.
21. Tang Z, Xie Y, Yang F, Huang Y, Wang C, Dai K, et al. Porous tantalum coatings prepared by vacuum plasma spraying enhance bmscs osteogenic differentiation and bone regeneration in vitro and in vivo. PLoSOne. 2013;8(6):e66263. Epub 2013/06/19. doi: 10.1371/journal.pone. 0066263PONE-D-13-04524 [pii]. PMID: 23776648; PubMed Central PMCID: PMC3679049.
22. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106(7):2472-83. Epub 2005/06/04. doi: 2004-12-4986 [pii] doi: 10.1182/blood-2004-12-4986 PMID: 15933061.
23. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, cultureexpanded human mesenchymal stem cells in vitro. J Cell Biochem. 1997;64(2):295-312. Epub 1997/02/01. doi: 10.1002/(SICI) 1097-4644 (199702) 64:2<295::AID-JCB12>3.0. CO;2-I [pii]. PMID: 9027589.
24. Wu JY, Aarnisalo P, Bastepe M, Sinha P, Fulzele K, Selig MK, et al. Gsalpha enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. The Journal of clinical investigation. 2011;121(9):3492-504. doi: 10.1172/JCI46406 PMID: 21804192; PubMed Central PMCID: PMC3163961.
25. Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, et al. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2010;25(2):211-21. doi: 10.1359/jbmr.090732 PMID: 19594306.
26. Dicembrini I, Mannucci E, Rotella CM. Bone: incretin hormones perceiveror receiver? Experimental diabetes research. 2012;2012:519784. doi: 10.1155/2012/519784 PMID: 22761607; PubMed Central PMCID: PMC3385656.
27. Papazafiropoulou A, Papanas N, Pappas S, Maltezos E. Role of endogenous GLP-1 and its agonists in osteopenia and osteoporosis: but we little know until tried. Current diabetes reviews. 2014;10(1):43-7. PMID: 24527734.
28. Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Endocrine. 2014. doi: 10.1007/s12020-014-0361-4 PMID: 25074632.
29. Dienelt A, Zur Nieden NI. Hyperglycemia impairs skeletogenesis from embryonic stem cells by affecting osteoblast and osteoclast differentiation. Stem cells and development. 2011;20(3):465-74. doi: 10. 1089/scd.2010.0205 PMID: 20939707.
30. Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, et al. High d (+) glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone. 2008;42(6):1122-30. doi: 10.1016/j.bone.2008. 02.006 PMID: 18378205; PubMed Central PMCID: PMC2696157.
31. Ellenbroek JH, Tons HA, Westerouen Van Meeteren MJ, De Graaf N, Hanegraaf MA, Rabelink TJ, et al. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia. 2013;56(9):1980-6. doi: 10.1007/s00125-013-2957-2 PMID: 23771206.
32. Schwartz AV, Margolis KL, Sellmeyer DE, Vittinghoff E, Ambrosius WT, Bonds DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes care. 2012;35(7):1525-31. doi: 10.2337/dc11-2184 PMID: 22723583; PubMed Central PMCID: PMC3379596.
33. Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 2000;141(3):1228-35. doi: 10.1210/endo.141.3.7366 PMID: 10698200.
34. Aoyama E, Watari I, Podyma-Inoue KA, Yanagishita M, Ono T. Expression of glucagon-like peptide-1 receptor and glucosedependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells. International journal of molecular medicine. 2014;34(2):475-82. doi: 10.3892/ijmm.2014.1787 PMID: 24866833.
35. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149(2):574-9. Epub 2007/11/28. doi: en. 2007-1292 [pii] doi: 10.1210/en. 2007-1292 PMID: 18039776.
36. Mabilleau G, Mieczkowska A, Irwin N, Flatt PR, Chappard D. Optimal bone mechanical and material properties require afunctional glucagon-like peptide-1 receptor. The Journal of endocrinology. 2013;219(1):59-68. doi: 10.1530/JOE-13-0146 PMID: 23911987.
37. Mieczkowska A, Mansur S, Bouvard B, Flatt PR, Thorens B, Irwin N, et al. Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2014. doi: 10.1007/s00198-014-2845-8 PMID: 25127672.
38. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89(5):755-64. PMID: 9182763.
39. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. The Journal of clinical investigation. 2004;113(6):846-55. doi: 10.1172/JCI19900 PMID: 15067317; PubMed Central PMCID: PMC362117.
40. Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011;11:12. Epub 2011/08/02. doi: 1472-6793-11-12 [pii] doi: 10.1186/1472-6793-11-12 PMID: 21801348; PubMed Central PMCID: PMC3162581.
41. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, De Boer AS, Drucker DJ, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-86. doi: 10.1210/en. 2009-1272 PMID: 20203154.
42. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE (-/-) mice. Endocrinology. 2013;154(1):127-39. doi: 10.1210/en. 2012-1937 PMID: 23183176.